{"filing":{"accession_number":"0001140361-26-035515","cik":"0001787297","ticker":"PASG","company_name":"Passage BIO, Inc.","form":"8-K","filing_date":"2026-09-02","report_date":"2026-09-02","primary_document":"ef20081513_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1787297/000114036126035515/ef20081513_8k.htm"},"events":[{"id":31423,"run_id":28830,"accession_number":"0001140361-26-035515","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"Passage Bio entered into an Amended and Restated Merger Agreement with Peregrine Merger Sub and Remix Therapeutics, representing a material acquisition and change of control with an aggregate equity value and concurrent financing of approximately $70 million and an outside closing date of December 24, 2026.","company_name":"Passage BIO, Inc.","ticker":"PASG","filing_date":"2026-09-02","form":"8-K","submitted_at":null,"items":[{"id":34294,"accession_number":"0001140361-26-035515","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This Item 1.01 discloses entry into an Amended and Restated Merger Agreement between Passage Bio, Peregrine Merger Sub, and Remix Therapeutics, representing a material acquisition and change of control. The filing describes a two-step merger structure with an aggregate equity value and concurrent financing of approximately $70 million, board approval and stockholder vote requirements, and an outside closing date of December 24, 2026—all hallmarks of a material M\u0026A transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T10:04:58.205226+00:00","company_name":"","ticker":null,"filing_date":""},{"id":34295,"accession_number":"0001140361-26-035515","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 3.02 explicitly addresses \"Unregistered Sales of Equity Securities\" and incorporates Item 1.01 by reference, indicating an unregistered equity issuance. This is a classic dilutive_issuance event. The cross-reference to Item 1.01 (which typically covers material agreements or transactions) suggests a significant capital-raising activity that would materially affect shareholders through dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T10:04:58.205226+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34294,"accession_number":"0001140361-26-035515","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This Item 1.01 discloses entry into an Amended and Restated Merger Agreement between Passage Bio, Peregrine Merger Sub, and Remix Therapeutics, representing a material acquisition and change of control. The filing describes a two-step merger structure with an aggregate equity value and concurrent financing of approximately $70 million, board approval and stockholder vote requirements, and an outside closing date of December 24, 2026—all hallmarks of a material M\u0026A transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T10:04:58.205226+00:00","company_name":"Passage BIO, Inc.","ticker":"PASG","filing_date":"2026-09-02"},{"id":34295,"accession_number":"0001140361-26-035515","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 3.02 explicitly addresses \"Unregistered Sales of Equity Securities\" and incorporates Item 1.01 by reference, indicating an unregistered equity issuance. This is a classic dilutive_issuance event. The cross-reference to Item 1.01 (which typically covers material agreements or transactions) suggests a significant capital-raising activity that would materially affect shareholders through dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T10:04:58.205226+00:00","company_name":"Passage BIO, Inc.","ticker":"PASG","filing_date":"2026-09-02"}]}